Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
Skye Bioscience (Nasdaq: SKYE) has appointed independent director Paul Grayson as Chairman of the Board, effective October 25, 2024. Grayson, who serves on Skye's Audit, Compensation and Nominating and Corporate Governance Committees, replaces former Chairman Punit Dhillon, who remains CEO and board member. The move aims to increase board independence and enhance governance structures. Grayson currently serves as CEO of Radionetics Oncology and has previous experience as CEO of Tentarix Biotherapeutics, with founding roles at Fate Therapeutics, BirdRock Bio, Senomyx, and Aurora Biosciences.
Skye Bioscience (Nasdaq: SKYE) ha nominato il direttore indipendente Paul Grayson come Presidente del Consiglio, con effetto dal 25 ottobre 2024. Grayson, che fa parte dei Comitati di revisione, compensi e nomina e governance aziendale di Skye, sostituisce l'ex Presidente Punit Dhillon, che rimane CEO e membro del consiglio. Questa mossa mira ad aumentare l'indipendenza del consiglio e migliorare le strutture di governance. Grayson attualmente ricopre il ruolo di CEO di Radionetics Oncology e ha precedenti esperienze come CEO di Tentarix Biotherapeutics, con ruoli fondatori in Fate Therapeutics, BirdRock Bio, Senomyx e Aurora Biosciences.
Skye Bioscience (Nasdaq: SKYE) ha nombrado al director independiente Paul Grayson como Presidente de la Junta, con efecto a partir del 25 de octubre de 2024. Grayson, quien forma parte de los Comités de Auditoría, Compensación y Nominación y Gobernanza Corporativa de Skye, reemplaza al ex Presidente Punit Dhillon, quien sigue siendo CEO y miembro de la junta. Este movimiento tiene como objetivo aumentar la independencia de la junta y mejorar las estructuras de gobernanza. Grayson actualmente es CEO de Radionetics Oncology y tiene experiencia previa como CEO de Tentarix Biotherapeutics, con roles fundadores en Fate Therapeutics, BirdRock Bio, Senomyx y Aurora Biosciences.
스카이 바이오사이언스(Nasdaq: SKYE)는 독립 이사 폴 그레이슨을 이사회 의장으로 임명했으며, 임기는 2024년 10월 25일부터 시작됩니다. 그레이슨은 스카이의 감사, 보상 및 임명과 기업 지배구조 위원회에서 활동하고 있으며, 전 의장인 푸닛 딜론을 대체합니다. 딜론은 CEO 겸 이사로 남아 있습니다. 이 결정은 이사회의 독립성을 높이고 지배구조를 개선하는 것을 목표로 하고 있습니다. 그레이슨은 현재 라디오네틱스 온콜로지의 CEO로 활동하고 있으며, 텐타릭스 바이오테라퓨틱스의 CEO로서의 경험이 있으며, 페이트 테라퓨틱스, 버드락 바이오, 세노믹스 및 오로라 바이오사이언스에서 창립 역할을 수행한 바 있습니다.
Skye Bioscience (Nasdaq: SKYE) a nommé le directeur indépendant Paul Grayson en tant que Président du Conseil, à compter du 25 octobre 2024. Grayson, qui siège aux Comités d'Audit, de Rémunération et de Nomination et de Gouvernance d'Entreprise de Skye, remplace l'ancien Président Punit Dhillon, qui reste PDG et membre du conseil. Cette décision vise à accroître l'indépendance du conseil et à améliorer les structures de gouvernance. Grayson est actuellement PDG de Radionetics Oncology et a une expérience antérieure en tant que PDG de Tentarix Biotherapeutics, ayant également joué des rôles fondateurs chez Fate Therapeutics, BirdRock Bio, Senomyx et Aurora Biosciences.
Skye Bioscience (Nasdaq: SKYE) hat den unabhängigen Direktor Paul Grayson zum Vorsitzenden des Aufsichtsrats ernannt, der ab dem 25. Oktober 2024 in Kraft tritt. Grayson, der in den Prüfungsausschüssen, dem Vergütungsausschuss sowie dem Nominierungs- und Corporate Governance-Ausschuss von Skye sitzt, ersetzt den ehemaligen Vorsitzenden Punit Dhillon, der weiterhin CEO und Vorstandsmitglied bleibt. Diese Entscheidung zielt darauf ab, die Unabhängigkeit des Aufsichtsrats zu erhöhen und die Governance-Strukturen zu verbessern. Grayson ist derzeit CEO von Radionetics Oncology und bringt frühere Erfahrungen als CEO von Tentarix Biotherapeutics mit, bei denen er auch Gründungsrollen in Fate Therapeutics, BirdRock Bio, Senomyx und Aurora Biosciences hatte.
- Improved corporate governance through separation of CEO and Chairman roles
- Appointment of experienced biotech executive with proven track record in leadership and company exits
- None.
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the Board has appointed independent director Paul Grayson as Skye’s new Chairman of the Board, effective October 25, 2024. Mr. Grayson currently serves as a member of Skye’s Audit, Compensation and Nominating and Corporate Governance Committees. Punit Dhillon, Skye’s Chief Executive Officer, will continue to serve as a member of the Board.
Punit Dhillon, Skye’s Chief Executive Officer and former Chairman of the Board, commented, “We have a high bar with respect to how we operate Skye and saw this as a suitable juncture to increase independence of the Board and management in order to improve governance structures and enhance oversight capabilities. We could not be more delighted to have Mr. Grayson accept Skye’s Board nomination to the role of Chairman. His appointment further advances efforts to fully utilize the best talent at this crucial phase of Skye’s development journey. Mr. Grayson is a successful biotechnology entrepreneur with a proven industry track record as a leader, and we look forward to his role in helping optimize the contribution of the Board in strategically guiding the development of our lead asset as a next-generation therapy in obesity and other metabolic, inflammatory and fibrotic conditions.”
Paul Grayson, Skye’s Chairman of the Board, said, “I am delighted to accept this appointment as Skye’s Chairman of the Board. Having participated in Skye’s journey to date, I applaud the professionalism of Skye’s management team and I believe there is a distinct opportunity for nimacimab’s peripheral CB1 inhibitor to play a broad role in metabolic diseases including obesity. I look forward to the work that lays before us and working through execution of the Company’s strategic roadmap and milestones to come.”
Paul Grayson currently serves as Chief Executive Officer of Radionetics Oncology. Recently he was the President and CEO of Tentarix Biotherapeutics, an oncology company focused on multi-functional biologics. His previous experiences additionally include founding roles at Fate Therapeutics, BirdRock Bio (acquired by Skye Bioscience), Senomyx (acquired by Firmenich), and Aurora Biosciences (acquired by Vertex Pharmaceuticals).
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to: statements regarding our product development, statements regarding the ability of nimacimab to treat obesity or related indications, and statements regarding the therapeutic potential of nimacimab. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
FAQ
Who is the new Chairman of Skye Bioscience (SKYE)?
What positions does Paul Grayson hold on Skye Bioscience's (SKYE) committees?
What is Paul Grayson's current role outside of Skye Bioscience (SKYE)?